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Abstract
Accurately predicting drug responses to cancer is an important problem hindering
oncologists’ efforts to find the most effective drugs to treat cancer, which is a core
goal in precision medicine. The scientific community has focused on improving
this prediction based on genomic, epigenomic, and proteomic datasets measured in
human cancer cell lines. Real-world cancer cell lines contain noise, which degrades
the performance of machine learning algorithms. This problem is rarely addressed
in the existing approaches. In this paper, we present a noise-filtering approach
that integrates techniques from numerical linear algebra and information retrieval
targeted at filtering out noisy cancer cell lines. By filtering out noisy cancer cell
lines, we can train machine learning algorithms on better quality cancer cell lines.
We evaluate the performance of our approach and compare it with an existing
approach using the Area Under the ROC Curve (AUC) on clinical trial data. The
experimental results show that our proposed approach is stable and also yields the
highest AUC at a statistically significant level.
1 Introduction
Cancer has a significant impact on public health worldwide and is the second leading cause of death
in the US [1]. In 2016, the American Cancer Society [2] predicted that 1,685,210 new cancer cases
will be diagnosed, resulting in 595,690 deaths attributable to cancer in the US. Many of these cancer
patients respond differently to the same cancer drug (i.e., during chemotherapy). These response
differences are attributable to environmental (i.e., external) factors such as tobacco, infectious
organisms, and an unhealthy diet, as well as to genetic (i.e., internal) factors such as inherited genetic
mutations, hormones, or immune conditions, and cancer cell heterogeneity, all of which make cancer
drug discovery very difficult [3, 4, 5, 6]. Because of the significant numbers of deaths associated
with cancer, its study has attracted the attention of researchers from numerous domains including
computational biology, machine learning, and data mining [7, 8, 9].
Many existing drug sensitivity prediction algorithms do not take sample quality into consideration
[10, 11], which degrades their performance in the real world. Cell lines of poor quality exist, especially
when cell lines are not screened against all of the compounds [12]. These existing approaches fail to
remove the poor cell lines, which correspond to noisy samples in machine learning terms, and this
failure leads to the degraded performance of machine learning algorithms [13].
Contribution: In this paper, we propose a learning approach that removes the noisiest cell lines,
allowing a model to be learned from better quality cell lines to improve the predictive performance.
Our proposed approach consists of three steps. First, we calculate a distance matrix that corresponds
to all the inner products of the rows of a given matrix constructed using the Manhattan distance of the
training input. Second, we adopt technique from linear algebra to project the training input on the
eigenvectors of the distance matrix to yield transformed training input that corresponds to feature
vectors with noise-filtered features. Third, we adopt information retrieval technique [14] to retrieve
(i.e., select) a subset of better quality cell lines with the associated drug responses from the training
set using the degrees between the training input cell lines and the corresponding transformed training
input cell lines, where smaller degrees denote better quality cell lines. Then, we apply a learning
algorithm to the better quality training set to induce (i.e., learn) a model used for prediction on the
test set. The learning algorithms considered here are support vector regression and ridge regression
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[11, 15]. We excluded other learning algorithms such as random forests [16] because of their poor
performance, as in [11]. As our experimental results show, the proposed approach outperforms the
baseline prediction algorithms proposed by Geeleher et al. [11].
Outline: Section 2 describes the details of our proposed approach. Section 3 reports the exper-
imental results, including the evaluation of our proposed approach against the baseline prediction
algorithms on clinical trial data pertaining to breast cancer and multiple myeloma. Section 4 concludes
the paper.
2 The Proposed Approach
Figure 1 outlines the proposed approach, which works as follows Consider the gene expression
profiles denoted byX ∈ Rm×n., which consists of m cell lines (i.e., samples) and n genes. Y =
(y1,..., ym)
T consists of the corresponding real-value drug responses to X. A training set is define
as S={(xi, yi)}mi=1, xi ∈ X and yi ∈ Y. A test set is defined as T = {x
′
i}pi=1,where x
′
i ∈ Rn. (B) We
compute the distance matrix D as
D = LLT (1)
where
L = [l(xi, xj)]ij ∈ Rm×m (2)
and
l(xi, xj) = ||xi − xj ||1, ∀ i, j = 1, ...,m. (3)
Note that D ∈ Rm×m, xi (xj ,respectively) is the ith (jth, respectively) feature vector of feature
matrix S, and ||xi − xj ||1 =
∑n
a=1 |xai − xaj | is the Manhattan distance between xi and xj . The
eigenvalues of the distance matrix D are denoted by λ1 < λ2 < ... < λm, and v1, v2, ..., vm denote
the corresponding eigenvectors. According to the Courant-Fischer Theorem [17], we then have
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Figure 1: Data flow diagram showing our proposed approach to predicting in vivo drug sensitivity.
v1 = arg min
z:||z||2=1
zTD z (4)
and
vl = arg min
z:||z||2=1, z⊥ span{v1,v2,...,vl−1}
zTD z. (5)
Let Vt = [v1, v2, ..., vt] be the matrix whose columns are the first t eigenvectors of the distance
matrix D with the smallest eigenvalues (in this study, t = 1.) We project the training input of cell
lines X onto Vt to obtain the transformed training input X ∈ Rm×n with noise-filtered features. That
is,
X = VtVTt X. (6)
(C) Compute the degrees between each training input xi ∈ X and the corresponding transformed
training input xi ∈ X for i=1..m
i∗ = arg min
i∈{1,2,...,m}
θi (7)
and
θi = cos
−1
(
xi. xi
||xi||2 ||xi||2
)
× 180
pi
. (8)
2
In this case, i∗ is the index of xi∗ ∈ X, whose degree is θi∗ . Denote by S = {(xi∗ , yi∗)}qi∗=1 ⊆ S
the reduced training set whose q feature vectors correspond to the training set with the smallest q
degrees (i.e., θi∗=1 < θi∗=2 < ... < θi∗=q where q < m). (D) A learning algorithm is called on the
training set S of size q to induce model h. (E) We apply model h to make predictions on the test set.
In the rest of this paper, we will refer to the prediction algorithms that employ our proposed approach
using the abbreviations PA+SVR+L, PA+SVR+S, and PA+RR (see Table 1).
Abbreviation Prediction Algorithm
PA+SVR+L The proposed approach using support vector regression with a linear kernel
PA+SVR+S The proposed approach using support vector regression with a sigmoid kernel
PA+RR The proposed approach using ridge regression
B+SVR+L The baseline approach using support vector regression with a linear kernel
B+SVR+S The baseline approach using support vector regression with a sigmoid kernel
B+RR The baseline approach using ridge regression
Table 1: Abbreviation of drug sensitivity prediction algorithms.
3 Experiments and Results
3.1 Datasets
The training sets correspond to an 482 × 6539 matrix and an 280 × 9115 matrix for breast cancer
and multiple myeloma, respectively. The test sets correspond to an 24 × 6538 matrix (excluding
labels) and an 188 × 9114 matrix (excluding labels) for breast cancer and multiple myeloma,
respectively. Cell lines expression data for breast cancer and multiple myeloma were download from
the ArrayExpress repository (accession number E-MTAB-783). The drug IC50 values for docetaxel
and bortezomib were downloaded from (http://genemed.uchicago.edu/˜pgeeleher/cgpPrediction/).
The clinical trial data for breast cancer (multiple myeloma, respectively) were downloaded from
the Gene Expression Omnibus (GEO) repository with accession numbers GSE350 and GSE349
(GSE9782, respectively) [18, 19]. The responses (i.e., labels) of the clinical trial data are categorical
(e.g., “sensitive” or “resistant”). These labels were clinically evaluated by the degree of reduction in
tumor size to the given drug [11]. The downloaded data were processed according to Geeleher et al.
[11].
3.2 Experimental Methodology
10-fold cross validation is not suitable in this study as labels of the testing sets are categorical while
the labels of the corresponding training sets are real values. Hence, to evaluate whether the proposed
approach exhibits stable superior performances as sample size changes, we reduced the sample size
for the training set by 1% for each run, until the reduction reached 4%. In other words, we performed
5 runs with sample sizes of (482, 478, 473, 468, 463) and (280, 278, 275, 272, 269) for the two real
datasets, respectively.
Each prediction algorithm was trained on the same given training set, whose labels were continuous,
to yield models. Then, each model was applied to the same test set to yield predictions, where the
accuracy of the prediction algorithms were measured using the Area Under the ROC Curve (AUC)
as in [11].
The software used in this work included support vector regression with linear and sigmoid kernels
in the LIBSVM package [20], ridge regression [11], and R code for processing the datasets and
performance evaluation [11]. We used R to write code for the prediction algorithms and to perform
the experiments.
3.3 Experimental Results
Table 2 and Table 3 show the AUCs of 6 docetaxel and bortezomib sensitivity prediction algorithms
on the clinical trial data for breast cancer and multiple myeloma, respectively. Columns “m” and
“d” show the number of cell lines and genes, respectively, in the training sets that were provided to
each prediction algorithm; we provided the same training sets to each prediction algorithm. Column
“q+PA” shows the number of selected (i.e., retrieved) cell lines that were used in PA+SVR+L,
PA+SVR+S, and PA+RR to learn the models.
Table 2 and Table 3 show that our prediction algorithms perform better than the baseline prediction
algorithms (i.e., B+SVR+L and B+SVR+S) and B+RR, the proposed prediction algorithm by Geeleher
et al [11]. The results are dominant compared to the other prediction algorithms on the clinical
trial data in terms of the AUC of each run and of MAUC. These results indicate the stability of the
proposed prediction algorithms.
m d PA+SVR+L PA+SVR+S PA+RR q+PA B+SVR+L B+SVR+S B+RR
482 6,538 0.842 0.878 0.821 478 0.835 0.842 0.814
478 6,538 0.807 0.871 0.814 474 0.814 0.871 0.814
473 6,538 0.814 0.878 0.821 469 0.800 0.864 0.821
468 6,538 0.828 0.864 0.828 464 0.821 0.857 0.821
463 6,538 0.857 0.864 0.821 459 0.835 0.857 0.821
MAUC - 0.829 0.871 0.821 - 0.821 0.858 0.818
Table 2: The AUC of docetaxel sensitivity prediction algorithms for breast cancer patients on the test
set. The algorithm with the highest AUC is shown in bold. MAUC is the mean AUC.
3
m d PA+SVR+L PA+SVR+S PA+RR q+PA B+SVR+L B+SVR+S B+RR
280 9,114 0.659 0.635 0.654 210 0.613 0.602 0.614
278 9,114 0.656 0.623 0.650 209 0.609 0.600 0.611
275 9,114 0.679 0.626 0.647 207 0.622 0.601 0.603
272 9,114 0.685 0.641 0.653 204 0.628 0.605 0.607
269 9,114 0.681 0.658 0.657 202 0.632 0.598 0.606
MAUC - 0.672 0.636 0.652 - 0.620 0.601 0.608
Table 3: The AUC of bortezomib sensitivity prediction algorithms for multiple myeloma patients on
the test set. The algorithm with the highest AUC is shown in bold. The MAUC is the mean AUC.
Figure 2 and Figure 3 show the predictions of three prediction algorithms on the test sets when
the prediction algorithms learned models from the training sets with sizes m=482 and m=280,
respectively. For PA+SVR+S in Figure 2(a), the difference between the predicted drug sensitivity in
breast cancer patients was highly statistically significant (P = 67 × 10−5 from a t-test) between
trial-defined sensitivity and resistant groups. The B+SVR+S (Figure 2(b)) and B+RR (Figure 2(c))
achieved significant results with P = 117 × 10−5 and P = 434 × 10−5 , respectively, from
t-tests. PA+SVR+L (Figure 3(a)) achieved highly significant results (P = 10 × 10−5 from a
t-test). The results of B+RR (Figure 3(b)) and B+SVR+L (Figure 3(c)) were also significant with
P = 261 × 10−5 and P = 556 × 10−5, respectively, from t-tests.
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Figure 2: Predictions of docetaxel sensitivity in breast cancer patients. Strip charts (a), (b), and
(c) show the differences in predicted drug sensitivity for individuals sensitive or resistant to
docetaxel treatment using PA+SVR+S, B+SVR+S, and B+RR prediction algorithms, while (d)
shows the ROC curves of the prediction algorithms, which reveal the proportion of true positives
compared to the proportion of false positives. ROC = receiver operating characteristic.
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Figure 3: Prediction of bortezomib sensitivity in multiple myeloma patients. The strip charts
and boxplots in (a), (b), and (c) show predicted drug sensitivity for in vivo responders and non-
responders to bortezomib using the PA+SVR+L, B+RR, and B+SVR+L prediction algorithms,
respectively. The ROC curve in (d) illustrates the estimated prediction accuracy of the prediction
algorithms.
4 Conclusion
In this paper, we proposed a noise-filtering approach that blends the following techniques: (1)
Numerical linear algebra to yield transformed training input corresponding to noise-filtered features;
(2) Information retrieval to retrieve better quality cancer cell lines from the training set according to
the minimum degrees between the training input and the transformed training input; (3) Machine
learning to learn a model from better quality, reduced-size training sets and perform predictions on
test sets. The proposed approach uses two machine learning algorithms: support vector regression
and ridge regression. Compared to an existing drug sensitivity approach, our proposed approach
results in higher and statistically significant AUC values when using clinical trial data.
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